Annals of Surgical Oncology

, Volume 3, Issue 1, pp 15–23 | Cite as

Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses

  • Gary R. Peplinski
  • Kangla Tsung
  • Jennifer B. Meko
  • Jeffrey A. Norton
Original Articles


Background: Cancer gene therapy expressing specific levels of multiple genes has not been adequately tested. This study investigates the antitumor effects of recombinant vaccinia viruses (recVVs) that express predictable levels of single and multiple cytokines in a passive immunization murine breast cancer (C3HBA) model.

Methods: Seventeen recVVs encoding different cytokine combinations under weak and strong VV promoters were constructed. Cytokine production was measured in vitro by enzyme-linked immunosorbent assay. Mice were immunized with infected C3HBA cells and rechallenged 10 days later with 106 parental tumor cells. Controls were treated with saline or recVVs not expressing cytokines. Tumors were measured for 24 days. Data were analyzed using Fisher’s exact test and the Breslow-Gehan-Wilcoxon test.

Results: recVVs encoding multiple cytokines induced secretion of each cytokine at predictable levels corresponding to VV promoter strength. Ten of 10 controls developed tumors by day 11 after rechallenge. recVVs producing large but not small amounts of murine granulocyte-macrophage colony-stimulating factor (GM-CSF) alone resulted in complete protection in all immunized mice (p=0.0003) for 24 days and disease-free survival (DFS) was significantly prolonged versus controls (p<0.001). GM-CSF under a weak promoter was also effective in combination with human interleukin-1β (hIL-1β; p=0.0220; DFS, p=0.031) or interferon-gamma (IFN-γ; p=0.0037; DFS, p=0.003). Effectiveness of hIL-1β and IFN-γ vaccines depended on cytokine combinations and not the amount of cytokine produced. IL-2 or tumor necrosis factor-alpha vaccines had no significant antitumor effect.

Conclusions: (a) recVVs can simultaneously express controllable levels of two cytokines; (b) tumor cells modified by recVVs generate systemic antitumor immunity; and (c) strength of immunity appears to be related to the amounts and specific cytokine(s) produced.

Key Words

Vaccinia virus Gene therapy Cytokines Neoplasm 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice.Science 1993;261:209–11.PubMedGoogle Scholar
  2. 2.
    Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer.Lancet 1992;339:715–21.PubMedGoogle Scholar
  3. 3.
    Russell SJ. Lymphokine gene therapy for cancer.Immunol Today 1990;11:196–200.PubMedGoogle Scholar
  4. 4.
    Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant.Science 1991;252:854–6.PubMedGoogle Scholar
  5. 5.
    Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy.Proc Natl Acad Sci U S A 1991;88:8039–43.PubMedGoogle Scholar
  6. 6.
    Jolly D. Viral vector systems for gene therapy.Cancer Gene Ther 1994;1:51–64.PubMedGoogle Scholar
  7. 7.
    Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy:in vivo gene transfer using recombinant vaccinia virus vectors.Cancer Res 1994;54:3325–8.PubMedGoogle Scholar
  8. 8.
    Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA.Gene 1983;25:21–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Davison AJ, Moss B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins.Nucl Acids Res 1990;18:4285–6.PubMedGoogle Scholar
  10. 10.
    Davison AJ, Moss B. Structure of vaccinia virus early promoters.J Mol Biol 1989;210:749–69.PubMedGoogle Scholar
  11. 11.
    Baldick CJ, Moss B. Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes.J Virol 1993;67:3515–27.PubMedGoogle Scholar
  12. 12.
    Davison AJ, Moss B. Structure of vaccinia virus late promoters.J Mol Biol 1989;210:771–84.PubMedGoogle Scholar
  13. 13.
    Moss B. Regulation of vaccinia virus transcription.Ann Rev Biochem 1990;59:661–88.PubMedGoogle Scholar
  14. 14.
    Earl PL, Moss B. Protein expression IV: expression of proteins in mammalian cells using vaccinia. In: Ausubel FM, Brent R, Kingston RE, et al.Current protocols in molecular biology. New York: Greene Publishing Associates and Wiley-Interscience, 1991;16.15.1–16.18.10.Google Scholar
  15. 15.
    Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1β.Ann Surg Oncol 1995;2:151–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Smith GL, Mackett M. The design, construction and use of vaccinia virus recombinants. In: Binns MM, Smith GL, eds.Recombinant poxviruses. Boca Raton, FL: CRC Press, 1992:81–122.Google Scholar
  17. 17.
    Mackett M, Smith GL, Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.J Virol 1984;49:857–64.PubMedGoogle Scholar
  18. 18.
    Chakrabarti S, Brechling K, Moss B. Vaccinia virus expression vector: coexpression of b-galactosidase provides visual screening of recombinant virus plaques.Mol Cell Biol 1985;5:3403–9.PubMedGoogle Scholar
  19. 19.
    Falkner FG, Moss B.Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors.J Virol 1992;62:1849–54.Google Scholar
  20. 20.
    Pardoll DM. Cancer vaccines.Immunol Today 1993;14:310–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Brochier B, Kieny MP, Costy F, et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine.Nature 1991;354:520–2.CrossRefPubMedGoogle Scholar
  22. 22.
    Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation.Nature 1984;311:750–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells byde novo expression of H-2K antigens following H-2 gene transfection.Nature 1985;315:301–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.Cancer Res 1994;54:5552–5.PubMedGoogle Scholar
  25. 25.
    Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.Science 1993;259:368–70.PubMedGoogle Scholar
  26. 26.
    Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 countereceptor for the T lymphocyte molecules CD28 and CTLA-4.Cell 1993;71:1093–102.Google Scholar
  27. 27.
    Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.Cancer Res 1990;50:7820–5.PubMedGoogle Scholar
  28. 28.
    Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinomain vivo.J Exp Med 1991;173:889–97.CrossRefPubMedGoogle Scholar
  29. 29.
    Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proc Natl Acad Sci U S A 1993;90:3539–43.PubMedGoogle Scholar
  30. 30.
    Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanomain vivo.Cancer Res 1994;54:182–9.PubMedGoogle Scholar
  31. 31.
    Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.Science 1991;254:713–6.PubMedGoogle Scholar
  32. 32.
    Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.Nature 1992;360:258–61.CrossRefPubMedGoogle Scholar
  33. 33.
    McGee DW, Beagley KW, Aicher WK, McGhee JR. Transforming growth factor-b and IL-1β act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6.J Immunol 1993;151:970–8.PubMedGoogle Scholar
  34. 34.
    Belardelli F, Ciolli V, Testa U, et al. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.Int J Cancer 1989;44:1108–16.PubMedGoogle Scholar
  35. 35.
    Takikawa O, Oku T, Yasui H, Yoshida R. Synergism between IFN-g and IL-1a/b in growth inhibition of an allografted tumor.J Immunol 1993;151:2070–6.PubMedGoogle Scholar
  36. 36.
    Tanaka T, Hu-Li J, Seder RA, Fazekas de St.Groth B, Paul WE. Interleukin 4 suppresses interleukin 2 and interferon-g production by naive T cells stimulated by accessory cell-dependent receptor engagement.Proc Natl Acad Sci U S A 1993;90:5914–8.PubMedGoogle Scholar
  37. 37.
    Ohe Y, Podack ER, Olsen KJ, et al. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells.Int J Cancer 1993;53:432–7.PubMedGoogle Scholar
  38. 38.
    Gosselin EJ, Wardwell K, Rigby WFC, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-g, and IL-3.J Immunol 1993;151:1482–90.PubMedGoogle Scholar
  39. 39.
    Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells.J Exp Med 1988;167:700–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Kostura MJ, Tocci MJ, Limjuco G, et al. Identification of a monocyte specific pre-interleukin 1b convertase activity.Proc Natl Acad Sci U S A 1989;86:5227–31.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc 1996

Authors and Affiliations

  • Gary R. Peplinski
    • 1
  • Kangla Tsung
    • 1
  • Jennifer B. Meko
    • 1
  • Jeffrey A. Norton
    • 1
  1. 1.From the Laboratory of Biological Therapy, Department of SurgeryWashington University School of MedicineSt. LouisUSA

Personalised recommendations